Koppert and Amoéba are partnering to introduce a new biofungicide.

AXPERA is their innovative biological crop protection solution, an amoeba lysate-based biofungicide for combating fungal diseases. Amoéba says that it expects to receive the final assessment report on its active substance from the European Food Safety Environment (EFSA) in the near future, which will pave the way for the use of its product AXPERA in Europe by the end of 2025.

“This MOU is a major milestone for the company and we are very proud to sign it with Koppert with whom we share the same DNA,” said Benoit Villers, chairman of Amoéba, “It is a recognition of the fact that we are now considered as an important player in the biocontrol area. I am really convinced that Koppert with its strong expertise in biocontrol is the right partner for a win-win deal.”

Added Martin Koppert, chief business officer of Koppert: “We are excited to collaborate with Amoéba to introduce this novel biofungicide and its unique mode of action against a wide range of key pathogens in various crops. After two years of preparations, we are ready to enter the next phase and solidify our partnership. In this phase, Koppert will contribute its operational expertise and commercial distribution strength to bring AXPERA to market.”

U.S. approval for AXPERA is expected mid-2025 (approval for the active substance was granted in 2022).

Over the next five months, the two companies will exclusively explore the opportunity of a close cooperation in areas such as distribution, production, registration, financing and product (co-) development of AXPERA and new biocontrol products.